Enovis Corp

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Medical Technology and Fabrication Technology. The Medical Technology segment develops, manufactures and distributes medical devices used for rehabilitation, pain management and physical therapy. The Fabrication Technology develops, manufactures and supplies consumable products and equipment. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Enovis Corp reports robust Q4 performance and optimistic 2023 outlook

Enovis Corp's Q4 2022 earnings call highlighted strong performance, growth in key segments, and margin improvements. The company is optimistic about revenue growth in 2023 and aims for further margin expansion. Challenges include margin improvement targets and addressing analyst inquiries.

Enovis Corp reports strong Q1 results, eyes global expansion opportunities

Enovis Corp's Q1 performance reflects robust organic growth, margin expansion, and strategic acquisitions in the foot and ankle market. With a focus on innovation and international expansion, the company aims to sustain growth momentum and capitalize on market opportunities. Challenges include managing market dynamics and integrating future acquisitions effectively.

Enovis Corp reports robust Q2 performance and raises full-year guidance

Enovis Corp's Q2 performance showcased strong growth and margin expansion across segments, supported by strategic progress.
Raised full-year guidance reflects confidence in achieving organic sales growth and financial targets.
While challenges exist in market dynamics and operational efficiency, the company's strengths and opportunities position them for continued success.

Enovis Corp reports robust Q3 results, eyes growth through strategic acquisitions

Enovis Corp's Q3 performance reflects strong growth, margin improvement, and increased guidance, supported by strategic acquisitions.
The company's emphasis on integration, M&A activities, and operational efficiency positions it for sustained growth.
While challenges in maintaining growth and managing acquisitions exist, Enovis Corp's focus on opportunities for expansion and margin enhancement is promising.

Enovis Corp reports robust Q4 performance and optimistic outlook for 2024

Enovis Corp's Q4 2023 performance reflects strong revenue growth, margin expansion, and strategic acquisitions, setting the stage for a promising 2024.
The company's strengths lie in organic growth, competitive leadership, and a focus on innovation, while challenges include margin pressures and segment growth dynamics.
Opportunities abound for Enovis in market expansion, product refinement, and revenue enhancement, requiring careful navigation of challenges and external factors.
With a solid financial foundation, strategic outlook, and focus on sustainable growth, Enovis is poised for continued success and market leadership in the med tech sector.

Enovis Corp reports strong Q1 performance, eyes growth opportunities

Enovis Corp's Q1 2024 performance reflects robust revenue growth, margin improvement, and increased guidance, underpinned by strategic initiatives in product innovation and cross-selling.
While facing integration challenges and supply constraints, the company is poised to capitalize on opportunities like Arvis adoption, shoulder product launch, and margin expansion.
Analyst inquiries highlighted key areas for Enovis Corp's focus, signaling a proactive approach to addressing challenges and leveraging growth prospects in the market.

Enovis Corp (ENOV) reports strong Q2 growth despite integration challenges

Enovis Corp (ENOV) delivered robust Q2 results, showcasing revenue growth, margin improvement, and progress in acquisitions. While facing integration challenges, the company remains focused on strategic initiatives to drive future growth and enhance shareholder value.

Enovis Corp (ENOV) reports robust Q3 performance and tightens revenue guidance

Enovis Corp (ENOV) showcased strong financial performance in Q3 2024, driven by revenue growth and margin expansion across key segments.
While challenges like dissynergies and market dynamics were discussed, the company remains optimistic about future growth prospects.
Strategic strengths in business segments and a tightened revenue guidance underscore Enovis Corp's commitment to sustained performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

Enovis Corporation (NYSE:ENOV ) Q1 2022 Earnings Conference Call May 10, 2022 8:00 AM ET Company Participants Christopher Hix - Executive Vice President & Chief Financial Officer Matthew Trerotola - Chief Executive Officer Conference Call Participants Jeff Johnson - Robert W. Baird & Co. Matthew Mishan - KeyBanc Capital Markets Vijay Kumar - Evercore ISI Josh Jennings - Cohen Operator Good day and thank you for standing by.

Enovis Corporation (ENOV) CEO Matthew Trerotola on Q1 2022 Results - Earnings Call Transcript

Enovis (ENOV) delivered earnings and revenue surprises of 8.82% and 177.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Enovis (ENOV) Tops Q1 Earnings and Revenue Estimates

Wilmington, DE, May 10, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology growth company formerly known as Colfax Corporation, today announced its adjusted stand-alone financial results for the first quarter of 2022.   At the beginning of its second quarter on April 4, 2022, Colfax Corporation spun-off its industrial manufacturing business, ESAB Corporation, in a tax-free distribution to shareholders and renamed itself Enovis.

Enovis Announces First Quarter 2022 Adjusted Stand Alone Results

Wilmington, DE, April 14, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology growth company formerly known as Colfax Corporation, today announced that it will issue a press release on the morning of Tuesday, May 10, 2022 providing pro forma financial results for the first quarter of fiscal year 2022.

Enovis Schedules First Quarter 2022 Earnings Release and Conference Call

Colfax

ESAB Corp

PROG Holdings

S&P Global

NEW YORK , March 30, 2022 /PRNewswire/ -- ESAB Corp. (NYSE: ESAB) will be added to the S&P MidCap 400 effective prior to the opening of trading on Tuesday, April 5. Effective prior to the opening of trading on Wednesday, April 6, S&P MidCap 400 constituent PROG Holdings Inc. (NYSE: PRG) will replace Fiesta Restaurant Group Inc. (NASD: FRGI) in the S&P SmallCap 600.

ESAB Set to Join S&P MidCap 400; PROG Holdings to Join S&P SmallCap 600

News for Enovis Corp Stock (ENOV)